Abstract
Rationale
Buprenorphine has a long duration of action that allows less than daily dosing for opioid dependence, but pharmacologic characterization of buprenorphine’s duration of effects over multiple days is incomplete.
Objectives
This study assessed opioid blockade and spontaneous withdrawal effects of buprenorphine/naloxone (B/N) over a 98-h period.
Materials and methods
Residential opioid-dependent volunteers (n = 8) were maintained, in randomized sequence, on each of three different daily sublingual B/N doses (8/2, 16/4, 32/8 mg). After 2 weeks on each maintenance dose, participants underwent challenge sessions on each weekday for 1 week. Challenges consisted of within-session, ascending dose administration of IM hydromorphone (H: 0, 6, and 12 mg). During that week, active B/N dose was given only on Monday; double-blind placebo was administered on the remaining weekdays. Thus, these sessions assessed the extent of both opioid blockade and spontaneous withdrawal at 2, 26, 50, 74, and 98 h after the last active B/N dose.
Results
All three maintenance doses provided substantial but incomplete blockade against opioid agonist effects for 98 h. The extent of blockade diminished steadily but modestly over this time and did not differ as a function of B/N maintenance dose. In general, participants did not report marked spontaneous opioid withdrawal, although mild withdrawal effects were observed as time since the last active B/N dose increased. However, withdrawal did not differ as a function of B/N maintenance dose.
Conclusions
These findings suggest that B/N doses greater than 8/2 mg provide minimal incremental value in terms of opioid blockade and withdrawal suppression.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Amass L, Bickel WK, Higgins ST, Badger GJ (1994) Alternate-day dosing during buprenorphine treatment of opioid dependence. Life Sci 54:1215–1228
APA (2000) Diagnostic and statistical manual of mental disorders (text revision), 4th edn. American Psychiatric Association, Washington
Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE (1988) Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther 247:47–53
Bickel WK, Amass L, Crean JP, Badger GJ (1999) Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacology (Berl) 146:111–118
Boas RA, Villiger JW (1985) Clinical actions of fentanyl and buprenorphine. The significance of receptor binding. Br J Anaesth 57:192–196
Fraser HF, Van Horn GD, Martin WR, Wolbach AB, Isbell H (1961) Methods for evaluating addiction liability. (A) “Attitude” of opiate addicts toward opiate-like drugs, (B) A short-term “direct” addiction test. J Pharmacol Exp Ther 133:371–387
Fudala PJ, Jaffe JH, Dax EM, Johnson RE (1990) Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin Pharmacol Ther 47:525–534
Griffiths RR, Bigelow GE, Liebson I (1983) Differential effects of diazepam and pentobarbital on mood and behavior. Arch Gen Psychiatry 40:865–873
Gross A, Jacobs EA, Petry NM, Badger GJ, Bickel WK (2001) Limits to buprenorphine dosing: a comparison between quintuple and sextuple the maintenance dose every 5 days. Drug Alcohol Depend 64:111–116
Harris DS, Jones RT, Welm S, Upton RA, Lin E, Mendelson J (2000) Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend 61:85–94
Hill JL, Zacny JP (2000) Comparing the subjective, psychomotor, and physiological effects of intravenous hydromorphone and morphine in healthy volunteers. Psychopharmacology (Berl) 152:31–39
Jasinski DR (1977) Assessment of the abuse potentiality of morphine-like drugs (methods used in man). In: Martin WR (ed) Drug addiction I. Springer, Berlin Heidelberg New York, pp 197–258
Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE (1995) Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug Alcohol Depend 40:27–35
Johnson RE, Strain EC, Amass L (2003) Buprenorphine: how to use it right. Drug Alcohol Depend 70:S59–S77
Kolb L, Himmelsbach CK (1938) Clinical studies of drug addiction. III. A critical review of the withdrawal treatments with method of evaluating abstinence syndromes. Am J Psychiatry 94:759–799
Ling W, Wesson DR (2003) Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug Alcohol Depend 70:S49–S57
McLeod D, Griffiths RR, Bigelow GE, Yingling J (1982) An automated version of the digit symbol substitution test (DSST). Behav Res Methods Instrum 14:463–466
McQuay HJ, Moore RA (1995) Buprenorphine kinetics in humans. In: Cowan A, Lewis JW (eds) Buprenorphine: combatting drug abuse with a unique opioid. Wiley, New York, pp 137–147
Petry NM, Bickel WK, Badger GJ (1999) A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence. Clin Pharmacol Ther 66:306–314
Petry NM, Bickel WK, Badger GJ (2001) Examining the limits of the buprenorphine interdosing interval: daily, every-third-day and every-fifth-day dosing regimens. Addiction 96:823–834
Reitan RM (1958) Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills 8:271–276
Rosen MI, Wallace EA, McMahon TJ, Pearsall HR, Woods SW, Price LH, Kosten TR (1994) Buprenorphine: duration of blockade of effects of intramuscular hydromorphone. Drug Alcohol Depend 35:141–149
Schottenfeld RS, Pakes J, O’Connor P, Chawarski M, Oliveto A, Kosten TR (2000) Thrice-weekly versus daily buprenorphine maintenance. Biol Psychiatry 47:1072–1079
Schuh KJ, Walsh SL, Stitzer ML (1999) Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans. Psychopharmacology (Berl) 145:162–174
Stoller KB, Bigelow GE, Walsh SL, Strain EC (2001) Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berl) 154:230–242
Strain EC, Preston KL, Liebson IA, Bigelow GE (1992) Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. J Pharmacol Exp Ther 261:985–993
Strain EC, Preston KL, Liebson IA, Bigelow GE (1993) Precipitated withdrawal by pentazocine in methadone-maintained volunteers. J Pharmacol Exp Ther 267:624–634
Strain EC, Preston KL, Liebson IA, Bigelow GE (1995) Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone. J Pharmacol Exp Ther 272:628–638
Strain EC, Walsh SL, Preston KL, Liebson IA, Bigelow GE (1997) The effects of buprenorphine in buprenorphine-maintained volunteers. Psychopharmacology (Berl) 129:329-338
Strain EC, Stoller K, Walsh SL, Bigelow GE (2000) Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. Psychopharmacology (Berl) 148:374–383
Strain EC, Walsh SL, Bigelow GE (2002) Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine. Psychopharmacology (Berl) 159:161–166
Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE (1994) Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 55:569–580
Walsh SL, June HL, Schuh KJ, Preston KL, Bigelow GE, Stitzer ML (1995) Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology (Berl) 119:268–276
Acknowledgements
Supported by US Public Health Service Scientist Development Award K02 DA00332 and R01 DA08045 from the National Institute on Drug Abuse.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Correia, C.J., Walsh, S.L., Bigelow, G.E. et al. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period. Psychopharmacology 189, 297–306 (2006). https://doi.org/10.1007/s00213-006-0571-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-006-0571-4